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Objectives. The effects of propafenone, a predominantly class IC 
antiarrhythmic drug, on defibrillation and pacing thresholds were 
evaluated in patients undergoing cardioverter-defibrillator im- 
plantation. 
Background. Previous studies have shown that the class IC 
agents encainide and flecainide may increase the energy require- 
ments for pacing and defibrillation. Animal studies with 
propafenone have shown inconsistent results regarding its effect 
on defibrillation energy requirements. This report investigated the 
effects of propafenone on defibrillation and pacing thresholds in 
humans. 
Methods. After cardioverter-defibrillator implantation, 47 pa- 
tients were enrolled in a double-blind, three-way parallel, random- 
ized trial of 450 mg/day (Group 1) or 675 rag/day (Group 2) of oral 
propafenone or placebo (Group 3) for 3 to 7 days. Predischarge 
defibrillation and pacing thresholds after treatment were com- 
pared with baseline thresholds obtained at implantation. 
Results. There was no statistically significant difference be- 
tween implantation and predischarge defibrillation thresholds in 
the three groups (Group 1: [mean -+ SE] 11.0 + 1.3 vs. 12.1 -+ 
1.5 J; Group 2:11.5 + 1.1 vs. 13.6 -+ 1.3 J; Group 3:12.5 -+ 1.2 vs. 
13.3 + 1.6 J), and no significant difference between treatment 
groups was found with a 0.86 power to detect a 5-J difference 
between groups. Paired pulse width pacing thresholds at 2.8 V 
were compared in 14 patients. A small increase of 0.02 ms was 
noted at predischarge testing in patients treated with propafenone 
and placebo. 
Conclusions. Short-term oral propafenone (450 and 675 rag/day) 
does not significantly affect defibrillation or pacing thresholds. 
Concomitant use of propafenone in patients with implantable 
cardioverter-defibriHators with recurrent ventricular or atrial tachy- 
arrhythmias should not interfere with proper device function. 
(J Am CoU Cardiol 1996;28:418-22) 
The effects of antiarrhythmic drugs on pacing and defibrillation 
thresholds continue to be clinically relevant because 50% to 
70% of patients with cardioverter-defibrillators require antiar- 
rhythmic drug therapy (1), and up to 14% require implantation 
of a separate pacemaker for intermittent bradycardia support 
(2,3). Furthermore, paroxysmal trial fibrillation is commonly 
seen in patients with a cardioverter-defibrillator, nd its occur- 
rence can result in inappropriate herapy by the cardioverter- 
defibrillator (4). Propafenone is being increasingly used for 
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treating patients with paroxysmal trial fibrillation because the 
drug is relatively effective at maintaining sinus rhythm and 
controlling the ventricular rate during atrial fibrillation. In 
addition, propafenone is relatively safe because the incidence 
of serious side effects, including proarrhythmia, is low (5). 
Propafenone has been used in -7% of patients with a defi- 
brillator (1) to slow the rate of ventricular tachycardia and 
reduce the frequency of recurrences (6). 
Unfortunately, several studies have shown that many anti- 
arrhythmic drugs increase defibrillation energy requirements 
(7-15) and postshock pacing thresholds (16,17). Flecainide and 
encainide have been shown to increase the defibrillation 
energy requirements in normal animal models (8,11-15). Like 
flecainide and encainide, propafenone is also a predominantly 
class IC drug that blocks sodium channels (class I), but it 
differs in that it is both a weak beta-adrenergic blocking agent 
(class II) and calcium channel blocking agent (class IV). 
Conflicting reports on the effects of propafenone on defi- 
brillation thresholds have been reported in an open chest 
normal canine model. In one study, intravenous propafenone 
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increased the energy required for successful defibrillation by 
59% to 75% compared with that in control dogs (7). Using a 
similar protocol, Moore (personal communication) found no 
significant increase in the acute defibrillation threshold after 
intravenous propafenone loading and a statistically significant 
decrease in the energy required for 50% probability of success- 
ful defibrillation after 7 days of oral propafenone therapy. 
The present multicenter, prospective, double-blind, placebo- 
controlled study was designed to evaluate the effects of 
propafenone on defibrillation and pacing thresholds in patients 
undergoing cardioverter-defibrillator implantation. 
Methods  
Study patients. The study included 49 patients (34 men, 15 
women) undergoing routine cardioverter-defihrillator implan- 
tation at six participating centers. Appropriate Investigational 
Review Committee approvals were obtained by each investi- 
gator in accordance with the U.S. Code of Federal Regulations 
for this study. Patients ---21 years old with a history of 
ventricular tachycardia or ventricular fibrillation who were 
scheduled to undergo cardioverter-defibrillator implantation 
without concomitant cardiac surgery were enrolled in the study 
after providing written informed consent. Patients were ex- 
cluded from the study if they had 1) previous intolerance to 
propafenone; 2) treatment with amiodarone within the previ- 
ous 6 months; 3) New York Heart Association functional class 
III or IV congestive heart failure; 4) unstable angina; 5) left 
ventricular ejection fraction <20%; 6) myocardial infarction or 
cardiac surgery within the previous 2 months; 7) history of 
neurologic symptoms, acute congestive heart failure or angina 
pectoris precipitated by arrhythmic episodes; 8) Wolff- 
Parkinson-White syndrome with paroxysmal trial fibrillation; 
9) systolic blood pressure <85 mm Hg; 10) arrhythmia due to 
acute electrolyte disturbance or other reversible acute illness; 
11) significant hepatic or renal failure; 12) digitalis toxicity; 13) 
pregnancy or lactation; or 14) defibrillation threshold that 
could not be determined during implantation or exceeded 20 J. 
Study design. After cardioverter-defibrillator implanta- 
tion, 48 patients entered a double-blind, randomized, three- 
way parallel treatment phase of the study: 15 patients were 
randomized to Group i (propafenone, 450 mg/day), 15 to Group 
2 (propafenone, 675 mg/day) and 18 to Group 3 (placebo). 
One patient was excluded after cardioverter-defibrillator implant- 
ation for a defibrillation threshold of 24 J. All three groups were 
treated with three divided dosages for a minimum of 3 days after 
the cardioverter-defibrillator implantation. Plasma concentra- 
tions of propafenone and one of its major metabolites, 
5-hydroxypropafenone (18), were determined aily by a high 
pressure liquid chromatographic assay described elsewhere (19). 
No other additional antiarrhythmic agents were adminis- 
tered during the study. Patients were allowed to continue 
beta-blockers, calcium antagonists and digitalis that had been 
started before enrollment in the study. Patients could be 
censored from the study if they developed serious medical 
complications or if an antiarrhythmic drug was warranted. 
Table 1. Pulse Generators Implanted 
No. of 
Device Patients 
Biphasic shock 
Medtronic 7219 16 
Medtronic 7202 1 
CPI P2 5 
CPI PRX II 2 
Teleetronics Enguard 5 
Ventritex Cadence 6 
Intermedics RES-Q 1 
Monophasic shock 
Medtronic 7217 8 
CPI Ventrak 1600 2 
CPI Ventak PRX I 2 
Repeat esting for defibrillation and pacing thresholds was 
performed before hospital discharge. After predischarge t st- 
ing was complete, propafenone was discontinued, and patients 
were observed for at least 12 h before release from the 
hospital. 
Defibrillation and pacing threshold testing. Defibrillation 
and pacing thresholds were determined at cardioverter- 
defibrillator implantation and at predischarge t sting. A variety of 
pulse generators and lead systems were implanted at the six 
participating centers (Table 1). The majority of patients received 
transvenous, tiered-therapy, biphasic pacer cardioverter- 
defibrillators. Ventricular fibrillation was induced by alternating 
current, rapid ventricular pacing or a T wave shock to perform 
defibrillation threshold testing. Ventricular fibrillation was al- 
lowed to persist for at least 10 s before defibrillation at a selected 
energy was performed. The defibrillation threshold was defined as 
the lowest energy required to defibrillate at least two of three 
times using the step-down protocol described in Figure 1. The 
patient was included in the study only if two of three attempts at 
-<20 J were successful. 
Either pulse width or voltage pacing thresholds, or both, 
were measured at implantation and predischarge t sting. The 
specific method used was determined by the type of implant- 
able cardioverter-defibrillator and lead system. 
Statistical analysis. The number of study patients was 
sufficient o provide a 0.86 power to detect a 5-J difference in 
the mean defibrillation threshold between the three treatment 
groups at a 95% confidence l vel using a two-tailed test. 
Results are presented as mean value _+ SEM. The statistical 
model for the study was a comparison of the change in the 
mean defibrillation and pacing thresholds from implantation to 
predischarge t sting after treatment using paired t tests and 
analysis of variance for independent groups with repeated 
measures. Statistical significance was defined as p < 0.05. 
Results  
Patient disposition and demography. Of the 49 patients 
enrolled in the study, two were excluded from analysis because 
one had an implantation defibrillation threshold >20 J, and 
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Figure 1. Defibrillation threshold (DFT) test protocol schema used by 
the investigators atcardioverter-defibrillator implantation and during 
predischarge t sting. The initial defibrillation attempt was performed 
at or -15 J. If the selected shock energy successfully converted the 
rhythm, ventricular fibrillation was reinduced, and a lower shock 
energy was tested in 5-J decrements. If a selected energy failed, a high 
energy rescue shock was delivered, ventricular fibrillation was rein- 
duced, and a subsequent defibrillation attempt was made at the next 
higher energy level. If 15 J failed, then 20 J was tested. The defibril- 
lation threshold was defined as the lowest energy to defibrillate at least 
two of three times. 
ventricular fibrillation at predischarge testing could not be 
induced in the other. Table 2 summarizes the patient charac- 
teristics for the remaining 47 patients (15 patients in Group 1, 
14 in Group 2 and 18 in Group 3). There were no significant 
differences in the three groups with respect o the presence of 
coronary artery disease, age or left ventricular ejection frac- 
tion. Thirty-nine percent of patients underwent prior coronary 
artery bypass graft surgery, and 31% had defibrillators im- 
planted for sudden cardiac death. 
The mean defibrillation thresholds obtained at implanta- 
tion and predischarge t sting for the three treatment groups 
Table 2. Clinical Characteristics and Mean Defibrillation Thresholds 
for 47 Study Patients 
Group 1 Group 2 Group 3 
(PFN 450 rag/day) (PFN 675 rag/day) (placebo) 
(n = 15) (n : 14) (n = 18) 
Ischemic heart 11 8 12 
disease 
Age (yr) 65 +_ 4 64 + 3 63 ± 2 
LVEF (%) 36 + 4 44 + 4 45 _+ 3 
Range 15-60 25-70 24-78 
Implantation DFT (J) 11.0 +_ 1.3 11.5 _+ 1.1 12.5 ± 1.2 
Range 5-20 5-16 6-20 
Predischarge DFT (J) 12.1 ± 1.5" 13.6 + 1.3' 13.3 _+ 1.6' 
Range 3-22 5-20 4-26 
*p = NS. Except where noted, data re expressed asmean ± SE. DFT = 
defibrillation threshold; LVEF = left ventricular ejection fraction; PFN = 
propafenone. 
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Figure 2. Comparison of defibrillation thresholds measured in joules 
at cardioverter-defibrillator implantation and during predischarge 
testing for each patient by randomized group. Mean +- SE values are 
shown in parentheses. PFN = propafenone. 
are presented in Table 2. There was no statistically significant 
difference between implantation and predischarge testing in 
any of the three treatment groups. In addition, there was no 
statistically significant difference in the implantation or the 
predischarge defibrillation thresholds between the three 
groups. 
Figure 2 shows the individual defibrillation thresholds mea- 
sured for each patient by treatment group at the time of device 
implantation and at predischarge t sting. Compared with the 
implantation threshold, the predischarge defibrillation thresh- 
old was unchanged or had decreased in 9 (60%) of 15 Group 
1 patients, 7 (50%) of 14 Group 2 patients and 12 (66.6%) of 
18 Group 3 patients. An increase of up to 5 J was obtained in 
four patients (26.7%) in Group 1, five (35.7%) in Group 2 and 
three (16.7%) in Group 3. Predischarge defibrillation thresh- 
olds increased by >5 J in a minority of patients (two [13.3%], 
two [14.3%] and three [16.7%]) in the three respective groups. 
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Table 3. Analysis of Patients With Left Ventricular Ejection Fraction -<30% and >30% 
LVEF ~30% LVEF >30% 
Group 1 Group 2 Group 3 Group l Group 2 Group 3 
(n = 7) (n = 3) (n : 3) (n = 8) (n = ll) (n = 14) 
LVEF % 24_+ 2 27_+ 2 26_+ 2 46_+ 3 49-  4 50_+ 4 
Range 15-30 25-30 24-30 35-60 37-70 35-78 
Implantation DFT (J) 12.1 _+ 2.2 10.3 - 2.6 10.0 _+ 1.2 10.0 _+ 1.4 11.8 _+ 1.2 13.5 _+ 1.4 
Range 5-20 6-15 8-12 5-15 5-16 6-20 
Predischarge DFT (J) 13.0 + 2.3* 16.0 _+ 1.5' 9.7 _+ 3.2* 11.2 _+ 2.1' 12.9 _+ 1.6" 13.7 _+ 1.8' 
Range 3-20 14 -19 4 -15 5-22 5-20 5-26 
*p = NS. Except where noted, data are expressed as mean _+ SE. Abbreviations as in Table 2. 
Reduced left ventricular ejection fraction did not seem to 
alter the results. In a separate analysis of patients with a left 
ventricular ejection fraction -<30% and >30%, there were no 
statistically significant differences in the defibrillation thresh- 
olds between implantation and predischarge t sting for any of 
the three treatment groups (Table 3). 
Furthermore, the use of transvenous lead systems did not 
alter the outcome. A separate analysis of 41 of the 47 patients 
with transvenous lead systems was performed to determine 
whether any differences could be found in mean defibrillation 
threshold between implantation and predischarge t sting. The 
mean thresholds at implantation a d predischarge t sting were 
11.8 _+ 1.3 J and 12.9 _+ 1.6 J for Group 1 (n = 13), 10.9 _+ 1.2 
J and 13.6 _+ 1.5 J for Group 2 (n = 12) and 11.9 _+ 1.2 J and 
12.9 _+ 1.7 J for Group 3 (n = 16), respectively. There were no 
statistically significant differences among the three groups. 
All 47 patients had pacing thresholds measured at implan- 
tation and after 3 to 7 days of treatment. A comparison could 
be made in only 14 of the 47 patients in whom pacing 
thresholds were measured at 2.8 V at implantation and pre- 
discharge testing. Table 4 summarizes the pacing threshold 
data. Of the 14 patients, 7 received propafenone (3 received 
675 mg/day and 4 received 450 mg/day), and 7 received 
placebo. A combination of pulse widths and voltages limited 
comparisons of pacing thresholds inthe remaining 23 patients. 
A small, statistically significant difference in the pulse width 
pacing threshold was observed in the placebo group, but not 
for patients treated with propafenone. 
The mean plasma propafenone l vel on the day of predis- 
charge testing was 237 _+ 72 ng/ml for Group 1 patients and 
Table 4. Pulse Width Pacing Threshold Data Measured at 2.8 V for 
14 Patients 
Propafenone Placebo 
(n= 7)* (n =7) 
Implantation threshold (ms) 0.11 _+ 0.02 0.08 + 0.01 
Range 0.05-0.15 0.05-0.15 
Predischarge threshold (ms) 0.13 _+ 0.02 0.10 + 0.01t 
Range 0.06-0.2 0.06-0.18 
*Three patients received 675 mg/day, and four received 450 rag/day, tP : 
0.01 versus mean pacing threshold at implantation. Data are expressed as mean 
pulse width pacing threshold _+ SE. 
285 _+ 50 ng/ml for Group 2 patients. The mean plasma level 
for propafenone's active metabolite, 5-hydroxypropafenone, 
was 113 _+ 28 ng/ml for Group 1 patients and 144 + 21 ng/ml 
for Group 2 patients. There was no statistical significance 
between these two propafenone treatment groups. 
Discussion 
Most studies of the effects of antiarrhythmic drugs in 
humans and animal models report an increase in the defibril- 
lation energy requirements. Previous studies of the effects of 
propafenone on defibrillation energy requirements have shown 
inconsistent results and have been limited to normal dogs. 
These reports have limited applicability to humans with heart 
disease and reduced systolic function. 
To our knowledge, this is the first placebo-controlled, 
randomized study of the effect of propafenone on the defibril- 
lation thresholds in humans with ventricular tachycardia or a 
history of aborted sudden cardiac death due to ventricular 
fibrillation. The results demonstrate a small, clinically insignif- 
icant increase in ventricular defibrillation and pacing thresh- 
olds after short-term therapy with moderate doses of oral 
propafenone for 3 to 7 days. Such small increases in these 
thresholds do not appear to have a significant impact on the 
overall effectiveness of cardioverter-defibrillator or pacing 
therapy in the management of these patients. The small 
increase in the pulse width pacing threshold may be due to 
early lead-tissue changes that increase the acute pacing thresh- 
old in the first few weeks after pacing lead implantation. 
All the patients treated with propafenone in this study 
tolerated the drug well, without adverse effects on clinical 
cardiac function. Of the patients treated with propafenone 
(Groups 1 and 2), 10 with left ventricular ejection fractions 
-<30% tolerated propafenone without developing congestive 
heart failure. 
Study limitations. It is not known whether the defibrilla- 
tion thresholds remain stable with long-term therapy or at 
higher propafenone dosages (e.g., 900 mg/day), whereby non- 
linear pharmacokinetics may result in an increase in blood 
levels. The levels measured in this short-term study are at the 
low end of the therapeutic range (200 to 1,500 ng/ml). It is 
possible that at higher blood levels, an increase in the defibril- 
lation threshold may occur, and this may be significant in 
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patients with very low ejection fractions, as was seen in three 
patients with ejections fractions <30% who were treated with 
675 rag/day of propafenone. The mean defibrillation threshold 
for these patients increased from 10.3 to 16.0 J. 
Finally, the defibrillation data presented here may not be 
valid for propafenone-induced ventricular arrhythmias re- 
ported in 4% of patients treated with propafenone (Knoll 
Product Information). 
Conclusions. The short-term use of propafenone in mod- 
erate dosages for antiarrhythmic control in patients with 
cardioverter-defibrillators is probably safe and should not 
interfere with proper device function. It can help to improve 
the appropriateness of cardioverter-defibrillator therapy by 
controlling paroxysmal atrial fibrillation and ventricular tachy- 
cardia recurrences without significantly affecting defibrillation 
or pacing thresholds. 
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